# A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)

> **NCT07119931** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 34 (estimated)

## Conditions studied

- HCC

## Interventions

- **DRUG:** lparomlimab and Tuvonralimab Injection in Combination with HAIC and bevacizumab

## Key facts

- **NCT ID:** NCT07119931
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2027-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07119931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07119931, "A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07119931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*